Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ensuring access to HPV vaccines through integrated services: a reproductive health perspective</title><author><name sortKey="Pollack, Amy E" sort="Pollack, Amy E" uniqKey="Pollack A" first="Amy E" last="Pollack">Amy E. Pollack</name><affiliation><nlm:aff id="aff1">Columbia University Mailman School of Public Health, New York, NY, USA.</nlm:aff></affiliation></author><author><name sortKey="Balkin, Miranda" sort="Balkin, Miranda" uniqKey="Balkin M" first="Miranda" last="Balkin">Miranda Balkin</name><affiliation><nlm:aff id="aff2">Global Health Strategies, New York, NY, USA.</nlm:aff></affiliation></author><author><name sortKey="Edouard, Lindsay" sort="Edouard, Lindsay" uniqKey="Edouard L" first="Lindsay" last="Edouard">Lindsay Edouard</name><affiliation><nlm:aff id="aff3">United Nations Population Fund, New York, NY, USA.</nlm:aff></affiliation></author><author><name sortKey="Cutts, Felicity" sort="Cutts, Felicity" uniqKey="Cutts F" first="Felicity" last="Cutts">Felicity Cutts</name><affiliation><nlm:aff id="aff4">Department of Immunization, Vaccines and Biologicals, WHO, Geneva, Switzerland.</nlm:aff></affiliation></author><author><name sortKey="Broutet, Nathalie" sort="Broutet, Nathalie" uniqKey="Broutet N" first="Nathalie" last="Broutet">Nathalie Broutet</name><affiliation><nlm:aff id="aff5">Department of Reproductive Health and Research, WHO, 1211 Geneva 27, Switzerland.</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">17242759</idno><idno type="pmc">2636212</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636212</idno><idno type="RBID">PMC:2636212</idno><idno type="doi">10.2471/BLT.06.034397</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">000E82</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Ensuring access to HPV vaccines through integrated services: a reproductive health perspective</title><author><name sortKey="Pollack, Amy E" sort="Pollack, Amy E" uniqKey="Pollack A" first="Amy E" last="Pollack">Amy E. Pollack</name><affiliation><nlm:aff id="aff1">Columbia University Mailman School of Public Health, New York, NY, USA.</nlm:aff></affiliation></author><author><name sortKey="Balkin, Miranda" sort="Balkin, Miranda" uniqKey="Balkin M" first="Miranda" last="Balkin">Miranda Balkin</name><affiliation><nlm:aff id="aff2">Global Health Strategies, New York, NY, USA.</nlm:aff></affiliation></author><author><name sortKey="Edouard, Lindsay" sort="Edouard, Lindsay" uniqKey="Edouard L" first="Lindsay" last="Edouard">Lindsay Edouard</name><affiliation><nlm:aff id="aff3">United Nations Population Fund, New York, NY, USA.</nlm:aff></affiliation></author><author><name sortKey="Cutts, Felicity" sort="Cutts, Felicity" uniqKey="Cutts F" first="Felicity" last="Cutts">Felicity Cutts</name><affiliation><nlm:aff id="aff4">Department of Immunization, Vaccines and Biologicals, WHO, Geneva, Switzerland.</nlm:aff></affiliation></author><author><name sortKey="Broutet, Nathalie" sort="Broutet, Nathalie" uniqKey="Broutet N" first="Nathalie" last="Broutet">Nathalie Broutet</name><affiliation><nlm:aff id="aff5">Department of Reproductive Health and Research, WHO, 1211 Geneva 27, Switzerland.</nlm:aff></affiliation></author></analytic><series><title level="j">Bulletin of the World Health Organization</title><idno type="ISSN">0042-9686</idno><idno type="eISSN">1564-0604</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>In 2006, a quadrivalent human papillomavirus (HPV) vaccine was licensed, and another vaccine may be licensed soon. Little is known about the practical considerations involved in designing and implementing cervical cancer prevention programmes that include vaccination as a primary means of prevention. Although the vaccine may ultimately be indicated for both males and females, young girls, or girls and women aged 9–25 years, will be the initial candidates for the vaccine. This paper describes avenues for service delivery of HPV vaccines and critical information gaps that must be bridged in order to inform future sexual and reproductive health programming. It proposes the role that the sexual and reproductive health community, together with immunization and cancer control programmes, could have in supporting the introduction of HPV vaccines within the context of current health systems.</p></div></front></TEI><pmc article-type="other"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17242759</article-id><article-id pub-id-type="pmc">2636212</article-id><article-id pub-id-type="doi">10.2471/BLT.06.034397</article-id><article-categories><subj-group subj-group-type="heading"><subject>Policy and Practice</subject></subj-group></article-categories><title-group><article-title>Ensuring access to HPV vaccines through integrated services: a reproductive health perspective</article-title><trans-title-group xml:lang="fr"><trans-title>Garantir l’accès aux vaccins HPV grâce à un système de services intégrés : point de vue de la santé génésique</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title>Garantizar el acceso a las vacunas contra el PVH mediante servicios integrados: una perspectiva de salud reproductiva</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title>ضمان إتاحة لقاحات فيروس الورم الحليمي البشري من خلال </trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title>الخدمات المتكاملة: منظور الصحة الإنجابية </trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pollack</surname><given-names>Amy E</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Balkin</surname><given-names>Miranda</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Edouard</surname><given-names>Lindsay</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cutts</surname><given-names>Felicity</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Broutet</surname><given-names>Nathalie</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><collab>on behalf of the WHO/UNFPA Working Group on Sexual and Reproductive Health and HPV Vaccines</collab></contrib><aff id="aff1"><label>a</label>Columbia University Mailman School of Public Health, New York, NY, USA.</aff><aff id="aff2"><label>b</label>Global Health Strategies, New York, NY, USA.</aff><aff id="aff3"><label>c</label>United Nations Population Fund, New York, NY, USA.</aff><aff id="aff4"><label>d</label>Department of Immunization, Vaccines and Biologicals, WHO, Geneva, Switzerland.</aff><aff id="aff5"><label>e</label>Department of Reproductive Health and Research, WHO, 1211 Geneva 27, Switzerland.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to this author (email: <email xlink:href="broutetn@who.int">broutetn@who.int</email>).</corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2007</year></pub-date><volume>85</volume><issue>1</issue><fpage>57</fpage><lpage>63</lpage><history><date date-type="received"><day>06</day><month>7</month><year>2006</year></date><date date-type="rev-recd"><day>05</day><month>10</month><year>2006</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2006</year></date></history><permissions><copyright-statement>© World Health Organization (WHO) 2007. All rights reserved.</copyright-statement><copyright-year>2007</copyright-year></permissions><abstract><title>Abstract</title><p>In 2006, a quadrivalent human papillomavirus (HPV) vaccine was licensed, and another vaccine may be licensed soon. Little is known about the practical considerations involved in designing and implementing cervical cancer prevention programmes that include vaccination as a primary means of prevention. Although the vaccine may ultimately be indicated for both males and females, young girls, or girls and women aged 9–25 years, will be the initial candidates for the vaccine. This paper describes avenues for service delivery of HPV vaccines and critical information gaps that must be bridged in order to inform future sexual and reproductive health programming. It proposes the role that the sexual and reproductive health community, together with immunization and cancer control programmes, could have in supporting the introduction of HPV vaccines within the context of current health systems.</p></abstract><trans-abstract xml:lang="fr"><title>Résumé</title><p>En 2006, un vaccin quadrivalent contre le papillomavirus humain (HPV) a été homologué et un autre vaccin de ce type pourrait l’être aussi prochainement. On sait encore peu de choses sur les aspects pratiques qui devront être pris en compte dans la conception et la mise en œuvre des programmes de prévention du cancer de l’utérus intégrant la vaccination comme moyen de prévention primaire. Bien que ce vaccin puisse à terme être indiqué pour les individus des deux sexes, les jeunes filles, c’est-à-dire les filles et les femmes de 9 à 25 ans, seront les premières candidates pour la vaccination. Ce document présente les canaux de délivrance des vaccins HPV et les lacunes dans les connaissances critiques et devant être comblées pour que l’on dispose d’un support pour l’élaboration des futurs programmes de santé sexuelle et génésique. Il expose le rôle de soutien que la communauté des professionnels de la santé sexuelle et génésique, en collaboration avec les programmes de vaccination et de lutte anticancéreuse, pourrait avoir dans l’introduction des vaccins HPV dans le contexte des systèmes de santé actuels.</p></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><p>En 2006 se autorizó una vacuna tetravalente contra el papilomavirus humano (PVH), y dentro de poco se podría autorizar otro tipo de vacuna. Poco se sabe sobre las consideraciones prácticas que fundamentan el diseño y aplicación de los programas de prevención del cáncer cervicouterino que incluyen la vacunación como una medida primordial de prevención. Aunque la vacuna podría estar indicada a la larga tanto para los hombres como para las mujeres, los candidatos iniciales a la vacuna serán las niñas, o las muchachas y mujeres de 9 a 25 años. En el presente documento se describen los medios que pueden emplearse para administrar las vacunas contra el PVH y las lagunas de información que habría que colmar para orientar los futuros programas de salud sexual y reproductiva. Se apunta el papel que podría desempeñar la comunidad de salud sexual y reproductiva, junto con los programas de inmunización y lucha contra el cáncer, en apoyo de la introducción de las vacunas contra el PVH en el contexto de los actuales sistemas de salud.</p></trans-abstract><trans-abstract xml:lang="ar"><title>ملخص </title><p>تم إجازة لقاح فيروس الورم الحليمي البشري الرباعي التكافؤ في عام 2006، كما سيتم إجازة لقاح جديد عما قريب. والحق أننا لا يتوفر لدينا سوى القدر اليسير من المعلومات عن الاعتبارات العملية الخاصة بتصميم وتنفيذ برامج الوقاية من سرطان عنق الرحم من خلال اللقاحات، كوسيلة أولية للوقاية. وبالرغم من أن اللقاح قد يوصف للرجال والنساء في نەاية المطاف، إلا أن اللقاح سيُعطى أول ما يعطى للفتيات، وصغار الفتيات، والنساء ممن تـتراوح أعمارەن بين سن التاسعة والخامسة والعشرين. وستـتناول ەذە الوثيقة توضيح سُبُل تقديم خدمات التطعيم بلقاح فيروس الورم الحليمي البشري، وسد الفجوات المعلوماتية حتى يُستەدي بەا في وضع برامج الصحة الإنجابية والجنسية في المستقبل. كما تقترح الدور الذي قد تضطلع بە البرامج المجتمعية المعنية بالصحة الإنجابية والجنسية، وبرامج التمنيع ومكافحة السرطان، لدعم إدخال لقاحات فيروس الورم الحليمي البشري في سياق النظم الصحية الراەنة. </p></trans-abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E829 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000E829 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.32. |  |